1.Acute Pulmonary Edema during General Anesthesia and after Operation - 3 cases report.
Korean Journal of Anesthesiology 1980;13(1):83-88
The authors have experienced three cases of pulmonary edema during anesthesia and after operation: 3 cases in urgent condition with toxemia and ectopic gestation underwent general anesthesia. One patient had no specific past history and the other two had cardiac or pulmonary problems before operation. In these cases, we believe that relative overloading of fluids in an undetected valular heart disease, preexisting pulmonary disease, severs preeclamptic condition, and myocardial depressant were the causative factors. High Fio2, with IPPB, diuretics, digitalis, dopamine and albumine were given immediately and so full recovery was observed in 4 hours to 3 days. There are many causes, prevention, and treatment for acute pulmonary edema. But believe that preoperative evaluation, intraoperative monitoring, prompt recognition and attention by the anesthetists are the most important preventive and therapeutic measures.
Anesthesia
;
Anesthesia, General*
;
Digitalis
;
Diuretics
;
Dopamine
;
Heart Diseases
;
Humans
;
Intermittent Positive-Pressure Breathing
;
Lung Diseases
;
Monitoring, Intraoperative
;
Pregnancy
;
Pulmonary Edema*
;
Toxemia
2.Accidental Total Spinal Block during Lumbar Epidural Anesthesia .
Korean Journal of Anesthesiology 1979;12(2):176-178
This is a case report of accidental total spinal block during epidural anesthesia with 1.5% lidocaine 20 ml for hemorrhoidectomy in a 25 year old male. It could have been avoided by; a) careful technical application. b) aspiration of spinal fluid and c) use of a test dose. Management consists of the administration of a vasopressor usually with assistance of respiration until dissipation of anesthesia. He was discharged in good condition without complications on the 7th postop, day.
Anesthesia
;
Anesthesia, Epidural*
;
Hemorrhoidectomy
;
Humans
;
Lidocaine
;
Male
;
Respiration
3.The Current Status of Enteral Feeding Management in General Surgical Ward.
Yun Jung KIM ; Young Mee BAEK ; So Yun KIM ; Mi Reu MOON ; Kyung Hee PARK ; So Hee PAECK ; Moon Young SEO ; Sook Young OH ; Eun Ji LEE ; Hyun Bin LIM ; Ji Ye HWANG ; In Sun CHUNG ; Jae Kil LEE ; Kyung Sik KIM ; Chong Bai KIM
Journal of Clinical Nutrition 2015;7(1):23-27
PURPOSE: Development of a standardized guideline and assessment tool is necessary. Therefore, the aim is to investigate the current state of enteral feeding management and to develop a basis for a standardized guideline. METHODS: From July 1, 2010 through June 30, 2011, this study was conducted retrospectively for 100 patients who had enteral feeding more than once only in the Intensive Care Unit, after General Surgery at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. The analysis was based on the following factors; age, diagnosis, name of the operation, period of start and the end of enteral feeding, method of injection, flushing method, residual volumes of the stomach, location and the size of the tube, medication through tubing, and complications related to enteral feeding. RESULTS: The mean age of the patients was 60.5, 65 men and 35 women. There were 30 malignant tumors of the hepatobiliary system and pancreas, 8 gastric and duodenal cancer, 4 colon and rectal cancer, 11 peritonitis, hemoperitoneum, and bowel obstruction, and 47 others. The average period of performing enteral feeding was 11.7 days and the locations of enteral feeding tube were stomach 56%, jejunum 39%, duodenum 3%, and undescribed 2%. The methods of enteral feeding were as follows; continuous feeding 19%, cyclic feeding 75%, intermittent and bolus feeding 3%, respectively. Only 1% of patients were on flushing and 16% on stomach residual. The most common complication of enteral feeding was clogging of the tube (5%). CONCLUSION: Due to the lack of detailed charting related to enteral feeding, we were unable to analyze the statistics on the relevance of complication which was the primary endpoint. As a result, development of a standardized protocol on charting enteral feeding is suggested for optimal enteral nutritional support.
Colon
;
Diagnosis
;
Duodenal Neoplasms
;
Duodenum
;
Enteral Nutrition*
;
Female
;
Flushing
;
Hemoperitoneum
;
Humans
;
Intensive Care Units
;
Jejunum
;
Korea
;
Male
;
Nutritional Support
;
Pancreas
;
Peritonitis
;
Rectal Neoplasms
;
Residual Volume
;
Retrospective Studies
;
Seoul
;
Stomach
4.Cystatin C is a Valuable Marker for Predicting Future Cardiovascular Diseases in Type 2 Diabetic Patients.
Seung Hwan LEE ; Kang Woo LEE ; Eun Sook KIM ; Ye Ree PARK ; Hun Sung KIM ; Shin Ae PARK ; Mi Ja KANG ; Yu Bai AHN ; Kun Ho YOON ; Bong Yun CHA ; Ho Young SON ; Hyuk Sang KWON
Korean Diabetes Journal 2008;32(6):488-497
BACKGROUND: Recent studies suggest that serum Cystatin C is both a sensitive marker for renal dysfunction and a predictive marker for cardiovascular diseases. We aimed to evaluate the association between Cystatin C and various biomarkers and to find out its utility in estimating risk for cardiovascular diseases in type 2 diabetic patients. METHODS: From June 2006 to March 2008, anthropometric measurements and biochemical studies including biomarkers for risk factors of cardiovascular diseases were done in 520 type 2 diabetic patients. A 10-year risk for coronary heart diseases and stroke was estimated using Framingham risk score and UKPDS risk engine. RESULTS: The independent variables showing statistically significant associations with Cystatin C were age (beta = 0.009, P < 0.0001), hemoglobin (beta = -0.038, P = 0.0006), serum creatinine (beta = 0.719, beta < 0.0001), uric acid (beta = 0.048, P = 0.0004), log hsCRP (beta = 0.035, P = 0.0021) and homocysteine (beta = 0.005, P = 0.0228). The levels of microalbuminuria, carotid intima-media thickness, fibrinogen and lipoprotein (a) also correlated with Cystatin C, although the significance was lost after multivariate adjustment. Calculated risk for coronary heart diseases increased in proportion to Cystatin C quartiles: 3.3 +/- 0.4, 6.2 +/- 0.6, 7.6 +/- 0.7, 8.4 +/- 0.7% from Framingham risk score (P < 0.0001); 13.1 +/- 0.9, 21.2 +/- 1.6, 26.1 +/- 1.7, 35.4 +/- 2.0% from UKPDS risk engine (P < 0.0001) (means +/- SE). CONCLUSIONS: Cystatin C is significantly correlated with various emerging biomarkers for cardiovascular diseases. It was also in accordance with the calculated risk for cardiovascular diseases. These findings verify Cystatin C as a valuable and useful marker for predicting future cardiovascular diseases in type 2 diabetic patients.
Biomarkers
;
Cardiovascular Diseases
;
Carotid Intima-Media Thickness
;
Coronary Disease
;
Creatinine
;
Cystatin C
;
Fibrinogen
;
Hemoglobins
;
Homocysteine
;
Humans
;
Lipoprotein(a)
;
Risk Factors
;
Stroke
;
Uric Acid